STAT

-

قناة - البرامج: ‫٢‬

الأخبار

الأخبار

يتم التحديث كل أسبوعين
الأعمال

الأعمال

يتم التحديث أسبوعيًا

٢٣‏/٠١‏/٢٠٢٠

Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos

Are we dealing with a SARS redux? Has the FDA lost its teeth? And what do billionaires talk to each other about?

٢٣‏/٠١‏/٢٠٢٠

-

٢٢ من الدقائق
١٦‏/٠٦‏/٢٠٢٢

213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback

Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can anything stop the amyloid hypothesis? Longtime biotech investor Les Funtleyder joins us to explain why the recent interest rate hike is bad for biotech and just what it will take for the industry to get out of its slump. Then, vaccinologist and FDA adviser Paul Offit calls in to talk about the impending authorization of Covid-19 vaccines for young children and what it means for the future of the pandemic. We also explain the latest disappointing clinical trial in Alzheimer's disease and some perplexing data on Pfizer's Covid-19 antiviral.

١٦‏/٠٦‏/٢٠٢٢

-

٣٥ من الدقائق
١٠‏/١١‏/٢٠٢٢

234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine, and what the politicization of the pandemic means for the future of science in the U.S. We also discuss the incoming CEOs of Biogen and Seagen, plus a pair of biotech collapses.

١٠‏/١١‏/٢٠٢٢

-

٣٣ من الدقائق
١٨‏/٠٣‏/٢٠٢١

Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea

First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain the latest data on an Alzheimer's disease treatment from Eli Lilly and why it has polarized experts in the field. Finally, we make a modest proposal to the biotech industry: Give honesty a chance.

١٨‏/٠٣‏/٢٠٢١

-

٣٠ من الدقائق
٠٦‏/١٢‏/٢٠٢٣

93: Rep. Raul Ruiz on going from the emergency room to Congress

Before he joined Congress, Rep. Raul Ruiz, a Democrat from California, worked in another chaotic environment: the emergency department. Today, he says, he tries to bring his background in medicine and public health to policymaking. In particular, he has turned his attention to a shortage of infectious disease physicians that threatens U.S. preparedness for the next pandemic. Our conversation was based on his recent First Opinion essay, “The infectious disease doctor shortage threatens future pandemic preparedness.” Don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

٠٦‏/١٢‏/٢٠٢٣

-

٣٠ من الدقائق
٠٣‏/٠٦‏/٢٠٢١

Episode 163: Marilynn Marchione on covering the CRISPR babies scandal

First, we discuss why it's so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington correspondent Nicholas Florko joins us for a dive into the thousands of emails from Anthony Fauci made public this week, complete with a top-five countdown of messages both impactful and absurd. Finally, longtime Associated Press medical reporter Marilynn Marchione retired last week, and she calls in to talk about the biggest stories of her career.

٠٣‏/٠٦‏/٢٠٢١

-

٢٨ من الدقائق
٠٨‏/١٢‏/٢٠٢٢

237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

STAT's Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.

٠٨‏/١٢‏/٢٠٢٢

-

٣٦ من الدقائق
٢٥‏/٠٣‏/٢٠٢١

Episode 153: AstraZeneca and the very good, then quite bad, then deeply confusing week

We're devoting this week's episode to the week of whiplash news about AstraZeneca's Covid-19 vaccine, subject of a baffling international incident with consequences still unfolding. First, we explain the series of late-night announcements that made global headlines. Then, our STAT colleague Helen Branswell joins us to discuss the implications for AstraZeneca, vaccine confidence, and the global effort to get doses in arms. Finally, STAT's Matthew Herper calls in to talk about Pascal Soriot, the hard-charging AstraZeneca CEO whose previously feted boldness might have backfired when it came to Covid-19.

٢٥‏/٠٣‏/٢٠٢١

-

٢٧ من الدقائق
١٣‏/١٢‏/٢٠١٨

Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

١٣‏/١٢‏/٢٠١٨

-

٢٣ من الدقائق
٠٩‏/٠٦‏/٢٠٢٢

212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy

When is data "practice-changing"? How many Covid-19 vaccines do we need? And what does it mean when the FDA asks for more time? With the world's largest cancer conference just concluded, we explain the most important data presented at the meeting, including a blockbuster clinical trial that promises to change the treatment of advanced breast cancer. We also discuss an FDA controversy in the making, a pair of new Covid-19 vaccines, and the frustrating process of finding new treatments for depression.

٠٩‏/٠٦‏/٢٠٢٢

-

٣٦ من الدقائق

Voices from the frontiers of health and medicine

موقع الويب